Categories: News

Edison Issues Report on VinFast Auto (VFS)

London, United Kingdom–(Newsfile Corp. – December 15, 2025) – Edison issues report on VinFast Auto (NASDAQ: VFS).

VinFast Auto (VFS) is a Vietnamese pure-play electric vehicle (EV) manufacturer that has transitioned from internal combustion engines to a fully electric line up of EV passenger cars, e-scooters and e-buses. The company is leveraging its core competencies in Vietnam (one of the fastest-growing EV markets globally) and its integrated EV ecosystem to expand in India, Indonesia and the Philippines. In our view, VinFast combines a strong strategic position in Vietnam with a sizeable opportunity to extend that model into high-growth regional markets, balanced against the execution and capital risks typical of a fast-growing EV manufacturer.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website
www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com

+44 (0)20 3077 5700

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278062

Staff

Recent Posts

Understanding When to Use Fillers or Neurotoxins According to Dr. Ran Rubinstein

Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…

2 hours ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…

2 hours ago

Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…

2 hours ago

ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…

2 hours ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Company expects up to six-month review period per FDA guidelines  New longer-term clinical data demonstrating…

2 hours ago